Tadeusz Robak, MD, PhD, is Professor of Hematology at the Medical University of Lodz   and the Copernicus Memorial Hospital in Lodz, Poland. Professor Robak studied medicine at the Medical University of Lodz and was approved as haematologist in 1985.    He undertook further postgraduate training in 1983–1984 at Hammersmith Hospital and the Royal Postgraduate Medical School, London, UK. In 1996–2002 he was vice-rector and rector of the Medical University of Lodz. Professor Robak was Chair of the chronic lymphocytic leukaemia (CLL) subgroup of the Polish Adult Leukemia Study Group. Since 2011to 2019 he was the president of the Polish Society of Hematology.  He has written more than 600 journal articles, most published in well-regarded peer-reviewed journals, and numerous abstracts and books or book chapters. His special interests are in chronic lymphocytic leukemia, hairy cell leukemia and lymphoma, with particular emphasis on the use of purine analogues and targeted drugs in the treatment of these diseases. Professor Robak was principal investigator of several Polish multi-centre phase 3 trials of cladribine in CLL and hairy cell leukaemia.    He was also principal investigator of the large international trials (REACH and COMPLEMENT2) in relapsed/refractory CLL and LYM 3002 study in mantle cell lymphoma. He is   reviewer for numerous journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Cancer Treatment Reviews, Blood, Leukemia, Leukaemia and Lymphoma, Lancet, Lancet Oncology and others.  Professor Robak has been selected by the World Scientists Forum of the International Research Promotion Council (IRPC) for the “Eminent Scientist of the Year 2010” award in haematology-oncology. Since 2019 he is a member of the European School of Haematology Scientific Committee and full member of the IWCLL Board.